SciDEX

Main

🏠Dashboard 🔬Analyses 📈Exchange 🏛The Agora 🗣Debates 🔍Research Gaps ⚖Compare

Knowledge

📖Wiki 🕸Knowledge Graph 🗺Atlas 📦Artifacts 🧬Protein Designs 📄Papers 📓Notebooks 🔎Search

System

🏛Senate ⚔Quests 💰Resources 🔨Forge 📊Experiments 🤖Agents 🚦Status 📑Docs

Info

ℹVision ⭐Showcase 📽Demo

Dashboard Analyses Exchange Agora Debates Gaps

Wiki Graph Atlas Artifacts Protein Designs Papers Search

Senate Quests Resources Forge Status

Vision Showcase Demo

Home / Wiki / Experiment: Mechanism: Selective Vulnerability of Dopaminergic Neurons i

experiment 584 words KG: and 2026-03-26

kind:experiment section:experiments state:published

Contents

Mechanism: Selective Vulnerability of Dopaminergic Neurons in Parkinson's Disease

Knowledge Graph

Related Hypotheses (6)

Selective Acid Sphingomyelinase Modulation Therapy
Score: 0.65 Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.59 HDAC3-Selective Inhibition for Clock Reset
Score: 0.46 Pericyte Contractility Reset via Selective PDGFR-β Agonism
Score: 0.44 Osmotic Gradient Restoration via Selective AQP1 Enhancement
Score: 0.43

CX43 hemichannel engineering enables size-selective mitochon
Score: 0.41

Related Analyses (29)

APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived

TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · completed Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived Mitochondrial transfer between neurons and glia
neurodegeneration · archived TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · archived Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed Gene expression changes in aging mouse brain predicting neur
neurodegeneration · archived Gene expression changes in aging mouse brain predicting neur
neurodegeneration · failed Gene expression changes in aging mouse brain predicting neur
neurodegeneration · failed Gene expression changes in aging mouse brain predicting neur
neurodegeneration · failed Gene expression changes in aging mouse brain predicting neur
neurodegeneration · archived Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · archived Cell type vulnerability in Alzheimer's Disease (SEA-AD data)
neurodegeneration · failed Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived Cell type vulnerability in Alzheimers Disease (SEA-AD transc
neurodegeneration · archived Cell type vulnerability in Alzheimers Disease (SEA-AD transc
neurodegeneration · archived TREM2 Therapeutic Strategy Post-INVOKE-2
neurodegeneration · completed GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed Gut-Brain Axis Therapeutics for AD
neurodegeneration · completed Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · completed Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · completed Mitochondrial transfer between astrocytes and neurons
neurodegeneration · completed

Related Experiments (30)

ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40 Cytochrome Therapeutics
clinical · proposed · Score: 0.40 AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Thera
validation · proposed · Score: 0.40 AAV-LRRK2 IND-Enabling Study Design
clinical · proposed · Score: 0.40 AAV Serotype Comparison for LRRK2 Knockdown in PD
validation · proposed · Score: 0.40

Alpha-Synuclein SAA Kinetics Study — Biological Staging Back
clinical · proposed · Score: 0.40 Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio
clinical · proposed · Score: 0.40 Computational Modeling of Alpha-Synuclein Propagation in PD
validation · proposed · Score: 0.40 Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation
validation · proposed · Score: 0.40 Alpha-Synuclein Seed Amplification Assay Validation
clinical · proposed · Score: 0.40 Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation
exploratory · proposed · Score: 0.40 Antiviral Therapy Trial for Parkinson's Disease
clinical · proposed · Score: 0.40 Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson'
clinical · proposed · Score: 0.40 Axonal Transport Dysfunction Validation in Parkinson's Disea
clinical · proposed · Score: 0.40 cGAS-STING Pathway Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40 Chaperone-Mediated Autophagy Dysfunction in PD - Experiment
clinical · proposed · Score: 0.40 Combination Therapy Sequencing in Parkinson's Disease
validation · proposed · Score: 0.40 CRISPR Gene Correction Approaches for CBS/PSP
clinical · proposed · Score: 0.40 Alpha-Synuclein Staging and Spreading in DLB — Spatial Propa
validation · proposed · Score: 0.40 DNA Damage Repair Deficiency Validation Study in Parkinson's
clinical · proposed · Score: 0.40 Mechanism: Selective Vulnerability of Dopaminergic Neurons i
validation · proposed · Score: 0.40 Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40 Epigenetic Dysregulation Validation in Parkinson's Disease
clinical · proposed · Score: 0.40 Exercise-BDNF-Mitophagy Biomarker Study in PD
clinical · proposed · Score: 0.40 Ferroptosis Validation in Parkinson's Disease
clinical · proposed · Score: 0.40 GLP-1 Agonist Neuroprotection Mechanism in PD
clinical · proposed · Score: 0.40 Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40 Gut-Brain Axis Pathogenesis in Parkinson's Disease — Mechani
clinical · proposed · Score: 0.40 Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson
clinical · proposed · Score: 0.40 Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown
validation · proposed · Score: 0.40

Knowledge Graph (6 edges)

and implicated_in neurodegeneration

and data_in benchmark_ot_ad_answer_key:AND

h-0758b337 targets and

h-db6aa4b1 targets and

h-7d4a24d3 targets and

benchmark_ot_ad_answer_key:AND data_in and

SciDEX — scidex.ai — Dashboard | Atlas